BCL9 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte leukemia cell line, designed for targeted disruption of the BCL9 gene. This heterogeneous pool of edited cells enables robust loss-of-function studies without requiring single-cell cloning, providing a flexible model for interrogating Wnt/??-catenin signaling in a T-cell acute lymphoblastic leukemia (T-ALL) background.
The Jurkat host cell line was established from the peripheral blood of a 14-year-old male with acute T cell leukemia and is an immortalized T lymphocyte model extensively used in signal transduction research. Jurkat cells exhibit well-characterized T cell receptor (TCR) signaling cascades and rapid proliferation, making them an optimal platform for gene disruption experiments aimed at elucidating oncogenic signaling pathways.
BCL9 functions as a critical transcriptional co-activator in the canonical Wnt/??-catenin pathway. Upon Wnt ligand (e.g., WNT3A, WNT1) binding to Frizzled receptors and Dishevelled (DVL) activation, stabilized ??-catenin (CTNNB1) accumulates and translocates to the nucleus, where BCL9 bridges ??-catenin to the Pygopus co-activators (PYGO1/2) and TCF/LEF transcription factors (TCF7, TCF7L2, LEF1). This multiprotein complex recruits chromatin modifiers such as CREBBP and the BAF complex component SMARCA4 to drive expression of Wnt target genes, including MYC, CCND1 (cyclin D1), AXIN2, and other TCF-dependent loci. CRISPR-mediated BCL9 disruption abolishes this bridging function, thereby silencing Wnt-induced transcriptional output.
In Jurkat T-ALL cells, aberrant Wnt/??-catenin signaling contributes to leukemogenic proliferation and survival. BCL9 knockout eliminates the essential co-activator that couples ??-catenin to its downstream transcriptional machinery, resulting in diminished expression of mitogenic and anti-apoptotic target genes. Consequently, these polyclonal knockout cells exhibit reduced Wnt pathway activity, as measured by TOPFlash luciferase reporter assays, and provide a physiologically relevant system for dissecting BCL9-dependent oncogenic mechanisms and assessing the therapeutic potential of Wnt pathway antagonists.
These BCL9 knockout cells support a broad range of applications in functional genomics, cancer biology, and drug target validation. Researchers can employ western blotting to confirm BCL9 loss and assess ??-catenin levels, RT-qPCR to profile target gene expression (e.g., MYC, CCND1), and co-immunoprecipitation to study BCL9-??-catenin interactions. Flow cytometric analysis of cell cycle and proliferation assays enable functional phenotypic assessment, while RNA-seq provides transcriptome-wide insights into BCL9-dependent gene networks. For further technical details, please contact Ascent Research.
